{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:30:13Z","timestamp":1755801013010,"version":"3.44.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:29:11Z","timestamp":1729582151000},"page":"35-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovations in Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"43","author":[{"given":"Sarah E.","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.det.2024.08.003_bib1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib2","article-title":"Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune-mediated diseases: Report of two cases","volume":"35","author":"Ramos","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib3","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/ijd.15286","article-title":"Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy","volume":"60","author":"Wohlmuth-Wieser","year":"2021","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A\u00a0systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor- in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-\u03b1 agent\u2019","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000503606","article-title":"Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa","volume":"236","author":"Zouboulis","year":"2020","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib9","first-page":"615","article-title":"Increased doses of adalimumab are associated with clinical improvement of hidradenitis suppurativa","volume":"22","author":"Williams","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.003_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15691","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.08.003_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15266","article-title":"Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: report of two cases","volume":"35","author":"Ramos","year":"2022","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.det.2024.08.003_bib13","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.jid.2021.04.026","article-title":"Golimumab for the treatment of hidradenitis suppurativa in patients with previous TNF-\u03b1 treatment failure","volume":"141","author":"Melendez-Gonzalez","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.08.003_bib14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"issue":"10378","key":"10.1016\/j.det.2024.08.003_bib15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10443","key":"10.1016\/j.det.2024.08.003_bib17","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study","volume":"184","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.08.003_bib22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp Dermatol"},{"issue":"14","key":"10.1016\/j.det.2024.08.003_bib23","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.08.003_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2450401","article-title":"The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa","volume":"2017","author":"Jim\u00e9nez-Gallo","year":"2017","journal-title":"Mediat Inflamm"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a\u00a0randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.003_bib29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A\u00a0phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.08.003_bib32","series-title":"The cytokines of the immune System","first-page":"143","article-title":"Chapter 6 - cytokines of the immune System: interleukins","author":"Dembic","year":"2015"},{"issue":"10","key":"10.1016\/j.det.2024.08.003_bib33","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jdv.19252","article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study","volume":"37","author":"Kimball","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2024.08.003_bib34","doi-asserted-by":"crossref","first-page":"T755","DOI":"10.1016\/j.ad.2023.06.018","article-title":"The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study","volume":"114","author":"Rivera-D\u00edaz","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2024.08.003_bib36","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2926","article-title":"Efficacy and safety of risankizumab in hidradenitis suppurativa: a case series","volume":"102","author":"Repetto","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib37","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1111\/ajd.13559","article-title":"Tildrakizumab as a potential long-term therapeutic agent for severe Hidradenitis Suppurativa: a 15 months experience of an Australian institution","volume":"62","author":"Kok","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"16","key":"10.1016\/j.det.2024.08.003_bib38","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.3390\/ijms23169479","article-title":"IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications","volume":"23","author":"Iznardo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib40","first-page":"s286","article-title":"Spesolimab for hidradenitis suppurativa: a proof-of-concept study","volume":"7","author":"Alavi","year":"2023","journal-title":"J\u00a0Skin"},{"issue":"S1","key":"10.1016\/j.det.2024.08.003_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.08.003_bib43","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s13555-023-00956-6","article-title":"Emerging treatments and the clinical trial landscape for hidradenitis suppurativa Part I: topical and systemic medical therapies","volume":"13","author":"Fragoso","year":"2023","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.003_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203672","article-title":"Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature","volume":"13","author":"Hoffman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2024.08.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.100","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","author":"Kirby","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3, Supplement","key":"10.1016\/j.det.2024.08.003_bib52","doi-asserted-by":"crossref","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib53","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib55","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-term treatment with apremilast in hidradenitis suppurativa: a 2-year follow-up of initial responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.08.003_bib56","article-title":"Orismilast for the treatment of mild to severe hidradenitis suppurativa: week 16 data from OSIRIS, a Phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial","author":"Frederiksen","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib57","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acs.jmedchem.0c01955","article-title":"Discovery of LYS006, a potent and highly selective inhibitor of leukotriene A4 hydrolase","volume":"64","author":"Markert","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"12","key":"10.1016\/j.det.2024.08.003_bib58","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.jid.2020.04.011","article-title":"Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4","volume":"140","author":"Penno","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib59","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A\u00a0proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/bjd\/ljad224","article-title":"Has the time come to assess small-molecule\/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?","volume":"189","author":"Maronese","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.003_bib61","doi-asserted-by":"crossref","DOI":"10.5070\/D3259045519","article-title":"Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab","volume":"25","author":"Cline","year":"2019","journal-title":"Dermatol Online J"},{"issue":"4 Suppl 1","key":"10.1016\/j.det.2024.08.003_bib62","first-page":"9","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.det.2024.08.003_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15743","article-title":"Successful treatment of hidradenitis suppurativa and Crohn\u2019s disease with combined guselkumab and apremilast","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ijd.15124","article-title":"Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa","volume":"60","author":"Garelik","year":"2021","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib65","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jaad.2021.11.005","article-title":"Use of a punch biopsy tool as an alternative approach for incision and drainage of abscesses","volume":"86","author":"Blum","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2024.08.003_bib66","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jaad.2015.07.050","article-title":"Laser and light-based treatment options for hidradenitis suppurativa","volume":"73","author":"Hamzavi","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"author":"Jemec","key":"10.1016\/j.det.2024.08.003_bib67"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib69","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.08.003_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15210","article-title":"Hyperhidrosis treatments in hidradenitis suppurativa: a systematic review","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"author":"Whitley","key":"10.1016\/j.det.2024.08.003_bib71"},{"issue":"11","key":"10.1016\/j.det.2024.08.003_bib72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","article-title":"Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a Randomized Controlled Trial in a real-world setting","volume":"89","author":"Aarts","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.08.003_bib74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13555-020-00391-x","article-title":"Office-based surgical intervention for hidradenitis suppurativa (HS): a focused review for dermatologists","volume":"10","author":"Saylor","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib75","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/bjd\/ljad246","article-title":"Evaluating the efficacy of continuous wave carbon dioxide laser therapy in conjunction with biologics for the management of hidradenitis suppurativa","volume":"189","author":"Maghfour","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib76","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jaad.2020.11.016","article-title":"Office-based surgical treatment of hidradenitis suppurativa: the unroofing technique","volume":"87","author":"Brownstone","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.08.003_bib77","first-page":"2311","article-title":"Surgical treatment in hidradenitis suppurativa","volume":"11","author":"Shukla","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.det.2024.08.003_bib78","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jdv.19810","article-title":"Deroofing: a safe, effective and well-tolerated procedure in patients with hidradenitis suppurativa","volume":"38","author":"Krajewski","year":"2024","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib79","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamadermatol.2021.4741","article-title":"Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery","volume":"158","author":"Ravi","year":"2022","journal-title":"JAMA Dermatology"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2023.0784","article-title":"The critical need for reliable and clinically meaningful outcome measures for hidradenitis suppurativa","volume":"159","author":"Naik","year":"2023","journal-title":"JAMA Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib81","doi-asserted-by":"crossref","DOI":"10.2196\/27869","article-title":"Trends in hidradenitis suppurativa disease severity and quality of life outcome measures: scoping review","volume":"4","author":"Maghfour","year":"2021","journal-title":"JMIR Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.08.003_bib82","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamadermatol.2023.0797","article-title":"Validation of the hidradenitis suppurativa investigator global assessment: a novel hidradenitis suppurativa\u2013specific investigator global assessment for use in interventional trials","volume":"159","author":"Garg","year":"2023","journal-title":"JAMA Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.08.003_bib83","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:04:46Z","timestamp":1755695086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000755"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}